weeks 1-16 on tirzepatide Semaglutide GI rate / 44.2% nausea, 31.5% diarrhea, 23.4% constipation in STEP-1 (N=1,961) Tirzepatide GI rate / approximately 80% of patients on 15 mg reported at least one GI effect in SURMOUNT-1 (N=2,539) First-line fix / avoid high-sulfur foods (eggs, garlic, cruciferous vegetables) on injection days Medication option / simethicone (Gas-X, 125 mg) or bismuth subsalicylate (Pepto-Bismol) may reduce odor and frequency Serious warning / new right-upper-quadrant pain plus burping may signal gallbladder disease, not routine GI upset Discontinuation / roughly 7% of semaglutide 2.4 mg patients stopped due to GI side effects in STEP-1 Dose strategy / slower titration reduces GI burden without meaningfully reducing weight loss outcomes What Causes Sulfur Burps on GLP-1 Drugs GLP-1 receptor agonists slow gastric emptying as a deliberate pharmacological effect
Skin-related side effects Another side effect reported in the clinical trials was skin sensitivity to touch, pain, pressure and heat
From hormone optimization to IV therapy, medical weight loss, and advanced peptide treatments, our customized solutions are designed to enhance your vitality and energy levels
Read more in the caption: #BreakingNews #EmcurePharma #WeightManagement #PharmaInnovation #HealthcareIndia To view or add a comment, sign in : - US regulators have approved Novo Nordisks -- , the first oral obesity drug on the market
